Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Viking Therapeutics	Akebia Therapeutics	Spectrum Pharmaceuticals	Affimed	Crinetics Pharmaceuticals
Symbol	NASDAQ:VKTX	NASDAQ:AKBA	NASDAQ:SPPI	NASDAQ:AFMD	NASDAQ:CRNX
Price Information
Current Price	$5.99	$2.97	$3.01	$10.05	$17.18
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	1.8	1.5	1.6	1.8
Analysis Score	3.6	3.3	3.4	3.5	3.4
Community Score	3.5	2.7	2.8	2.9	2.2
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	1.7	0.8	0.8	3.3
Earnings & Valuation Score	0.0	1.3	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$16.44	$9.63	$9.75	$13.80	$35.00
% Upside from Price Target	174.53% upside	224.07% upside	224.46% upside	37.38% upside	103.73% upside
Trade Information
Market Cap	$462.30 million	$455.90 million	$461.95 million	$987.29 million	$567.44 million
Beta	2.02	2.11	2.51	2.81	1.24
Average Volume	1,347,705	6,110,728	2,578,586	3,290,440	143,135
Sales & Book Value
Annual Revenue	N/A	$335 million	$109.33 million	$23.96 million	$1.19 million
Price / Sales	N/A	1.36	4.23	41.21	476.84
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$3.83 per share	$3.32 per share	$1.69 per share	$0.57 per share	$4.84 per share
Price / Book	N/A	0.89	1.78	17.62	3.55
Profitability
Net Income	$-25,780,000.00	$-279,660,000.00	$-112,690,000.00	$-36,250,000.00	$-50,420,000.00
EPS	($0.36)	($1.63)	($1.14)	($0.56)	($2.09)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-126.86%	N/A	-172.01%	N/A
Return on Equity (ROE)	-13.57%	-68.51%	-98.90%	-99.24%	-43.35%
Return on Assets (ROA)	-13.14%	-34.01%	-69.77%	-37.40%	-39.73%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.24%	0.05%	N/A	N/A
Current Ratio	27.08%	2.15%	3.48%	2.24%	21.98%
Quick Ratio	27.09%	1.67%	3.48%	2.24%	21.98%
Ownership Information
Institutional Ownership Percentage	54.13%	68.98%	63.56%	52.33%	92.15%
Insider Ownership Percentage	3.70%	2.55%	5.04%	N/A	7.10%
Miscellaneous
Employees	18	379	175	137	93
Shares Outstanding	77.18 million	153.50 million	153.73 million	98.29 million	33.03 million
Next Earnings Date	4/29/2021 (Estimated)	5/4/2021 (Estimated)	5/6/2021 (Estimated)	6/22/2021 (Estimated)	5/14/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Not Optionable

Source	Headline
	Crinetics Pharmaceuticals Stock Is Showing Strong Insider Interest finance.yahoo.com - April 21 at 1:34 PM
	Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $16.55 americanbankingnews.com - April 21 at 12:54 PM
	Analyzing Alkermes (NASDAQ:ALKS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) americanbankingnews.com - April 17 at 2:40 PM
	Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 5.8% americanbankingnews.com - April 15 at 2:44 PM
	Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 8.1% americanbankingnews.com - April 13 at 2:00 PM
	What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares? finance.yahoo.com - April 12 at 8:50 AM
	Insider Buys Crinetics Pharmaceuticals Shares benzinga.com - April 9 at 1:25 PM
	Insider Buying: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Major Shareholder Buys 304,136 Shares of Stock americanbankingnews.com - April 9 at 10:32 AM
	Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $16.44 americanbankingnews.com - April 8 at 10:44 AM
	Brokerages Anticipate Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Will Announce Earnings of -$0.64 Per Share americanbankingnews.com - April 5 at 2:12 PM
	Piper Sandler Weighs in on Crinetics Pharmaceuticals, Inc.'s Q2 2021 Earnings (NASDAQ:CRNX) americanbankingnews.com - April 2 at 8:50 AM
	FY2021 EPS Estimates for Crinetics Pharmaceuticals, Inc. Cut by Cantor Fitzgerald (NASDAQ:CRNX) americanbankingnews.com - April 2 at 8:50 AM
	Brokers Offer Predictions for Crinetics Pharmaceuticals, Inc.'s Q1 2021 Earnings (NASDAQ:CRNX) americanbankingnews.com - April 2 at 8:00 AM
	Brokers Set Expectations for Crinetics Pharmaceuticals, Inc.'s Q1 2022 Earnings (NASDAQ:CRNX) americanbankingnews.com - April 1 at 9:54 AM
	Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Rating Reaffirmed by SVB Leerink americanbankingnews.com - April 1 at 8:16 AM
	Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Earnings Results, Misses Expectations By $0.08 EPS americanbankingnews.com - March 31 at 7:28 AM
	Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full ... apnews.com - March 31 at 4:37 AM
	Crinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation seekingalpha.com - March 31 at 12:35 AM
	Crinetics Pharmaceuticals, Inc. to Host Earnings Call finance.yahoo.com - March 30 at 6:32 PM
	Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - March 30 at 6:32 PM
	Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans ... apnews.com - March 24 at 7:43 AM
	Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results benzinga.com - March 24 at 7:35 AM
	Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on ... apnews.com - March 12 at 4:56 PM
	Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs finance.yahoo.com - March 12 at 4:56 PM
	Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing's Disease (CRN04894) Advances into Phase 1 Study benzinga.com - February 5 at 6:35 PM

Date	Company	Brokerage	Action
1/22/2021	Viking Therapeutics	Stifel Nicolaus	Reiterated Rating
10/29/2020	Viking Therapeutics	Raymond James	Boost Price Target
9/11/2020	Viking Therapeutics	William Blair	Reiterated Rating
9/10/2020	Viking Therapeutics	B. Riley	Reiterated Rating
9/1/2020	Viking Therapeutics	BTIG Research	Boost Price Target
8/31/2020	Viking Therapeutics	Chardan Capital	Boost Price Target
8/28/2020	Viking Therapeutics	HC Wainwright	Boost Price Target
7/29/2020	Viking Therapeutics	Oppenheimer	Reiterated Rating
6/4/2020	Viking Therapeutics	BMO Capital Markets	Initiated Coverage
5/2/2020	Viking Therapeutics	Maxim Group	Initiated Coverage
1/2/2020	Viking Therapeutics	SVB Leerink	Reiterated Rating
3/15/2021	Akebia Therapeutics	Cantor Fitzgerald	Initiated Coverage
1/29/2021	Akebia Therapeutics	JPMorgan Chase & Co.	Downgrade
9/4/2020	Akebia Therapeutics	Morgan Stanley	Lower Price Target
9/4/2020	Akebia Therapeutics	Mizuho	Lower Price Target
8/11/2020	Akebia Therapeutics	Needham & Company LLC	Initiated Coverage
5/6/2020	Akebia Therapeutics	Royal Bank of Canada	Boost Price Target
9/17/2020	Spectrum Pharmaceuticals	JMP Securities	Initiated Coverage
12/26/2019	Spectrum Pharmaceuticals	Guggenheim	Downgrade
3/15/2019	Spectrum Pharmaceuticals	Jefferies Financial Group	Reiterated Rating
3/30/2021	Affimed	Credit Suisse Group	Initiated Coverage
3/30/2021	Affimed	Wells Fargo & Company	Boost Price Target
8/9/2020	Affimed	Laidlaw	Reiterated Rating
10/11/2018	Affimed	SunTrust Banks	Lower Price Target
12/23/2019	Crinetics Pharmaceuticals	Roth Capital	Initiated Coverage
8/13/2018	Crinetics Pharmaceuticals	Piper Jaffray Companies	Initiated Coverage

(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources